If things are going well for Novo Nordisk, which beat forecasts on Tuesday evening, things are even better for Eli Lilly. Fourth-quarter profits were much better than expected as demand for its diet pill Zepbound soared.
Profit after tax came in at $6.6 billion, compared to $4.4 billion in the same period last year.
Management's forecast for the full year 2026 is also higher than analysts' forecasts.
